OncRef

Clinical Trial: NCT06894771

A Study of MK-4700 Alone or With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors (MK-4700-001)

Status:

COMPLETED

Phase:

Phase 1

Lead Sponsor:Merck Sharp & Dohme LLC
Information Provided By:Merck Sharp & Dohme LLC
Last Update Posted:2026-03-16

Study Overview

Brief Summary

The goal of this study is to learn about the safety of different doses of MK-4700 and if people tolerate them. The study will also measure what happens in a person's body over time when MK-4700 is given alone or with pembrolizumab (MK-3475) in order to find a dose that is safe, tolerated, and may work to treat certain types of cancer.

Official Title

A Phase 1 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-4700 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Conditions

Malignant Neoplasm

Intervention / Treatment

  • Biological: MK-4700
  • Biological: Pembrolizumab

Other Study ID Numbers

  • 4700-001
  • MK-4700-001

Start Date (Actual)

2025-04-23

Primary Completion Date (Actual)

2025-12-08

Study Completion Date (Actual)

2025-12-08

Enrollment (Actual)

5

Study Type

Interventional

Phase

Phase 1